The way business is carried out in the pharmaceutical industry has become extremely dynamic. For pharmaceutical giants such as GlaxoSmithKline, a multinational company based in England, mergers and acquisitions are no longer attractive. The real money is in offering investors to hold some of the rights to certain medications. Such is the case of Imitrex, a triptan drug often prescribed for the treatment of migraines.